関連する実験動画
Updated: Aug 18, 2026

14:39
Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma
Published on: November 4, 2010
bronchodilator サルブタモールへの過敏性 喘息患者で1日2回サルメトロールを投与した後のサルブタモールへの過敏性
1Department of Clinical Pharmacology, Ninewells Hospital, University of Dundee, UK.
Lancet (London, England)
|July 22, 1995
まとめ
サルメテロールの継続的な使用は,喘息患者のサルブタモールに対する支氣管拡張剤の反応を鈍らせる可能性があります. この研究では,病気のコントロールが維持されているにもかかわらず,サルメトロールで反応の減少とβ-2アドレノ受容体の密度が示されました.
科学分野:
- 薬理学 薬理学とは
- 呼吸器医学とは
- クリニック・トライアル 臨床試験
背景:
- 喘息管理におけるベータ-2アゴニストの定期的な使用については懸念がある.
- サルメトロールのような長作用ベータ-2アゴニスト (LABAs) はますます使用されています.
- 絶え間ないLABA曝露が急性支氣管拡張剤反応に与える影響は,評価する必要がある.
研究 の 目的:
- 継続的に1日2回サルメトロールを投与すると,サルブタモールに対する急性支氣管拡張剤の反応が鈍くなるかどうかを評価する.
- サルメトロール治療によるβ-2アドレノ受容体の密度の変化を調査する.
- 治療中の喘息のコントロールにおけるサルメトロールの有効性を評価する.
主な方法:
- 17人の喘息患者を対象とした双盲,プラセボ対照,クロスオーバー研究.
- 患者は,サルメトロル50mcgを1日2回,またはプラセボを4週間投与された.
- ヒスタミンチャレンジとサルブタモール用量反応曲線 (FEV1,PEFR) を測定した.
主要な成果:
- サルメトロール治療は,プラセボと比較してサルブタモールに対する支支柱管拡張剤の反応を著しく減少させた.
- 与えられたFEV1とPEFRの改善のために,それぞれ2.5倍と4倍のサルブタモール投与が必要でした.
- リンパ球β-2アドレノ受容体の密度は,サルメトロール投与後に有意に減少した.
結論:
- サルメテロールの継続的な使用は,サルブタモルの急性支氣管拡張効果を弱める可能性があります.
- ベータ-2アドレノ受容体の密度の低下が,この鈍感な反応の根底にある可能性があります.
- サルメトロールは,朝のPEFRの改善によって証明された喘息のコントロールを維持しました.
関連する概念動画
Asthma: Pathogenesis and Management
Asthma is a chronic pulmonary condition involving inflammation of the airways, hyper-reactivity, and reversible obstruction of the airways. This condition can significantly impact a person's quality of life, making breathing difficult and leading to distressing symptoms.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
Antiasthma Drugs: β2-Adrenoceptor Agonists
Bronchodilators are critical in managing asthma, a chronic respiratory condition characterized by airway constriction due to inflammation and hyper-reactivity. Specifically, bronchodilators ease this constriction by relaxing the bronchial muscles, facilitating easier breathing.
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce relaxation in these...
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce relaxation in these...
Antiasthma Drugs: Methylxanthines
Theophylline, a member of the methylxanthine class of bronchodilators, has long been used in asthma management. While its exact mechanism of action is not fully understood, it is believed to have multiple effects on various cellular processes.
Theophylline is thought to inhibit phosphodiesterase enzymes, increasing intracellular levels of cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP). This rise in cAMP and cGMP concentrations stimulates cardiac function,...
Theophylline is thought to inhibit phosphodiesterase enzymes, increasing intracellular levels of cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP). This rise in cAMP and cGMP concentrations stimulates cardiac function,...
COPD: Management Using Bronchodilators and Corticosteroids
Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
Asthma-IV: Diagnostic and Management
The diagnosis and management of asthma are comprehensive, encompassing clinical assessments, lung function tests, and pharmacological interventions. Here's an overview:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
Asthma III: Clinical Manifestations
Asthma presents with a characteristic pattern of episodic respiratory symptoms that reflect underlying airway inflammation, bronchoconstriction, and mucus hypersecretion. Although severity varies among individuals, certain clinical manifestations are considered hallmarks of the disorder and often guide diagnosis and assessment.Respiratory SymptomsA persistent cough is one of the most common early features of asthma. It is frequently dry and tends to worsen at night or in the early morning,...

